Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Melody Hermel; Abdul Mannan Khan Minhas; Colin Hinkamp; Maha Inam; Nikitha Murthy; Zohar Chai; Vashma Junaid; Adeel Khoja; Sana Sheikh; Leandro Slipczuk; Elizabeth Vaughan; Sandeep Mehta; Elizabeth Epstein; Salim S. Virani

doi:10.1007/S11883-025-01276-0

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Melody Hermel
, Abdul Mannan Khan Minhas
, Colin Hinkamp
, Maha Inam
, Nikitha Murthy
, Zohar Chai
, Vashma Junaid
, Adeel Khoja
, Sana Sheikh
, Leandro Slipczuk
, Elizabeth Vaughan
, Sandeep Mehta
, Elizabeth Epstein
, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Purpose of Review Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. Recent Finding Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); person-alized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Summary Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

Original language	English (US)
Article number	30
Journal	Current Atherosclerosis Reports
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/S11883-025-01276-0
Publication status	Published - 2025

Keywords

Acute Coronary Syndrome
Cardiovascular Disease, American Heart Association
Familial Hypercholesterolemia
Lipoprotein(a)
Prevention
Semaglutide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/S11883-025-01276-0

Cite this

Hermel, M., Minhas, A. M. K., Hinkamp, C., Inam, M., Murthy, N., Chai, Z., Junaid, V., Khoja, A., Sheikh, S., Slipczuk, L., Vaughan, E., Mehta, S., Epstein, E., & Virani, S. S. (2025). Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions. Current Atherosclerosis Reports, 27(1), Article 30. https://doi.org/10.1007/S11883-025-01276-0

@article{8a8319c8ab6c4ee2a6ce2b3eded1447e,

title = "Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions",

abstract = "Purpose of Review Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. Recent Finding Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH\_OLE); person-alized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Summary Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.",

keywords = "Acute Coronary Syndrome, Cardiovascular Disease, American Heart Association, Familial Hypercholesterolemia, Lipoprotein(a), Prevention, Semaglutide",

author = "Melody Hermel and Minhas, \{Abdul Mannan Khan\} and Colin Hinkamp and Maha Inam and Nikitha Murthy and Zohar Chai and Vashma Junaid and Adeel Khoja and Sana Sheikh and Leandro Slipczuk and Elizabeth Vaughan and Sandeep Mehta and Elizabeth Epstein and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.",

year = "2025",

doi = "10.1007/S11883-025-01276-0",

language = "English (US)",

volume = "27",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "1",

}

Hermel, M, Minhas, AMK, Hinkamp, C, Inam, M, Murthy, N, Chai, Z, Junaid, V, Khoja, A, Sheikh, S, Slipczuk, L, Vaughan, E, Mehta, S, Epstein, E & Virani, SS 2025, 'Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions', Current Atherosclerosis Reports, vol. 27, no. 1, 30. https://doi.org/10.1007/S11883-025-01276-0

TY - JOUR

T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

AU - Hermel, Melody

AU - Minhas, Abdul Mannan Khan

AU - Hinkamp, Colin

AU - Inam, Maha

AU - Murthy, Nikitha

AU - Chai, Zohar

AU - Junaid, Vashma

AU - Khoja, Adeel

AU - Sheikh, Sana

AU - Slipczuk, Leandro

AU - Vaughan, Elizabeth

AU - Mehta, Sandeep

AU - Epstein, Elizabeth

AU - Virani, Salim S.

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.

PY - 2025

Y1 - 2025

N2 - Purpose of Review Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. Recent Finding Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); person-alized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Summary Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

AB - Purpose of Review Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. Recent Finding Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); person-alized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Summary Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

KW - Acute Coronary Syndrome

KW - Cardiovascular Disease, American Heart Association

KW - Familial Hypercholesterolemia

KW - Lipoprotein(a)

KW - Prevention

KW - Semaglutide

UR - https://www.scopus.com/pages/publications/85218290606

U2 - 10.1007/S11883-025-01276-0

DO - 10.1007/S11883-025-01276-0

M3 - Review article

C2 - 39913067

AN - SCOPUS:85218290606

SN - 1523-3804

VL - 27

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 1

M1 - 30

ER -

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this